Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.57 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87178 | 1.00 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15203246 | 1.00 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL792570 | 0.99 | F10 (0.97) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL792571 | 0.99 | F10 (0.97) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Sulfuric Acid SCHEMBL793039 | 0.94 | F10 (0.88) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Sulfuric Acid SCHEMBL793040 | 0.94 | F10 (0.88) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Oxalic Acid SCHEMBL14861652 | 0.94 | F10 (0.88) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Acetic Acid SCHEMBL13737134 | 0.93 | F10 (0.86) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Acetic Acid SCHEMBL13736179 | 0.93 | F10 (0.86) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Acetic Acid SCHEMBL13738152 | 0.93 | F10 (0.86) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111265668-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| CN-109232551-B | Rivaroxaban isopropylidene impurity reference substance and preparation method thereof | 东南大学 | 2020-06-02 | — | — | CN | claimed |
| CN-109232551-A | Razaxaban isopropylidene impurity reference substance and preparation method thereof | 东南大学 | 2019-01-18 | — | — | CN | claimed |
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2014-12-25 | — | — | US | claimed |
| WO-2013120465-A1 | A PROCESS FOR THE PREPARATION OF RIVAROXABAN BASED ON THE USE OF (S)-EPICHLOROHYDRIN | ZENTIVA, K.S. (CZ) | 2013-08-22 | — | — | WO | claimed |
| EP-2616466-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | Medichem, S.A. (ES) | 2013-07-24 | — | — | EP | claimed |
| WO-2013105100-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-07-18 | — | — | WO | claimed |
| EP-2613787-A2 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | Symed Labs Limited (IN) | 2013-07-17 | — | — | EP | claimed |
| WO-2013098833-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2013-07-04 | — | — | WO | claimed |
| US-20130172554-A1 | PROCESSES FOR THE PREPARATION OF 4-MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2013-07-04 | — | — | US | claimed |
| WO-2013027225-A1 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2013-02-28 | — | — | WO | claimed |
| WO-2012035057-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | MEDICHEM S.A. (ES) | 2012-03-22 | — | — | WO | claimed |
| WO-2012032533-A2 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2012-03-15 | — | — | WO | claimed |
| EP-4552633-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AMORPHOUS SOLID SOLUTIONS OF RIVAROXABAN AND COPOVIDONE AND PREPARATION METHODS THEREOF | Zentiva K.S. (CZ) | 2025-05-14 | — | — | EP | disclosed |
| CN-115536651-B | Rivaroxad method for preparing class | 陕西汉江药业集团股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-115536651-A | Preparation method of rivaroxaban | 陕西汉江药业集团股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2012032533-A2 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| US-20110288294-A1 | Preparation process for an inhibitor of a blood clotting factor | ARCHIMICA GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| WO-2011080341-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011012321-A1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA, D.D., NOVO MESTO (SI) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288294-A1 | Preparation process for an inhibitor of a blood clotting factor | TFPI, F5, F11 | F10 10/4885CYP1A2 972/4885CYP3A4 484/4885 |
| US-20130172554-A1 | PROCESSES FOR THE PREPARATION OF 4-MORPHOLIN-3-ONE | TYR, CYP1B1, AAAS | F10 4199/4885CYP1A2 26/4885CYP3A4 7/4885 |
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | VKORC1, VKORC1L1, F2 | F10 11/4885CYP1A2 16/4885CYP3A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.